Trial
NCT00971126
Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
National Health Research Institutes, Taiwan
Collaborators
National Cheng-Kung University Hospital; Chang Gung Memorial Hospital
Condition
Hepatocellular Carcinoma
Intervention
sorafenib (Nexavar®), thalidomide (Thado®)
Why stopped
Two patients in the first dose level be counted as reaching DLT. DSMB recommend terminated early this trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-05-04